News | April 23, 2007

Enrollment Completed for Abiomed’s Impella 2.5 Pilot Trial

April 24, 2007 — Abiomed Inc. has announced completion of the enrollment of 20 patients in its pilot clinical trial of the Impella 2.5 Circulatory Support System. The trial will be completed after the company has concluded all necessary post-enrollment patient monitoring.

The pilot trial will study outcomes for patients undergoing high-risk angioplasty procedures at the trial sites of William Beaumont Hospital, Brigham and Women's Hospital, Massachusetts General Hospital, Texas Heart Institute, Cedars-Sinai Medical Center, Scripps Clinic and the Academic Medical Center in Amsterdam.

Abiomed will host a conference call and Webcast on April 27, 1 p.m. ET, to discuss data on its Impella 2.5 that was presented by Dr. Jose P. Henriques from the Academic Medical Center in Amsterdam, at the American College of Cardiology's (ACC) 56th Annual Scientific Sessions. That study, titled "Preliminary Experience of the MACH 2 Trial: Safety and Feasibility of Left Ventricular Support with the Impella Recover LP2.5 Device in Patients with Acute ST-Segment Elevation Myocardial Infarction," found that the Impella 2.5 improved cardiac function for pre-shock acute myocardial infarction (AMI or heart attack) as compared to conventional care including intra-aortic balloon pump (IABP) therapy.

To listen to April 27 conference call live, tune into the Webcast via http://investor.abiomed.com or dial 800-798-2801; the international number is 617-614-6205. The access code is 18688274. A replay of this conference call will be available beginning at 3 p.m. ET April 27 through May 4, 2007. The replay phone number is 888-286-8010; the international number is 617-801-6888. The replay access code is 95044880.

For more information visit www.abiomed.com.

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init